Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies
Real-world data reveals improved overall survival in transplant ineligible multiple myeloma patients in Japan, highlighting the impact of novel treatments.
Key Points
To evaluate survival differences in transplant-ineligible multiple myeloma patients in Japan and Taiwan.
Used a matching-adjusted indirect comparison (MAIC) with real-world data from Japan and Taiwan.
Data from Japan sourced from the Medical Data Vision (MDV) database covering over 30 million patients.
Taiwan data derived from the National Health Insurance Research Database covering over 99% of the population.
Included patients diagnosed with transplant-ineligible multiple myeloma between Jan 1 and Dec 31, 2020, over 20 years old.
Primary outcome was overall survival from treatment initiation to death.
Japanese patients had significantly longer overall survival compared to Taiwanese patients.
Unadjusted hazard ratios indicated a strong survival advantage for Japanese patients.
After MAIC adjustment, Japanese patients still showed an overall survival benefit, with hazard ratios confirming the trend.
Median survival time was not reached for Japan but was approximately 27 months for Taiwan.